Cargando…

Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer

SIMPLE SUMMARY: Pancreatic adenocarcinoma is predicted to be the 2nd cause of death by cancer in Western Countries in 2023. Most patients are diagnosed at an advanced stage for which chemotherapy is the main treatment. In this study we developed through an innovative approach, a simple nine genes bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piquemal, David, Noguier, Florian, Pierrat, Fabien, Bruno, Roman, Cros, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692046/ https://www.ncbi.nlm.nih.gov/pubmed/33143297 http://dx.doi.org/10.3390/cancers12113204

Ejemplares similares

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
por: Piquemal, David, et al.
Publicado: (2023)

Bacterial community characterization of water and intestine of the shrimp Litopenaeus stylirostris in a biofloc system
por: Cardona, Emilie, et al.
Publicado: (2016)

Transcriptomic study in women with trisomy 21 identifies a possible role of the GTPases of the immunity-associated proteins (GIMAP) in the protection of breast cancer
por: Mégarbané, André, et al.
Publicado: (2020)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Of Mice and Men: Divergence of Gene Expression Patterns in Kidney
por: Cheval, Lydie, et al.
Publicado: (2012)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
por: Eickhoff, A, et al.
Publicado: (2006)

Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines
por: Zechner, Dietmar, et al.
Publicado: (2017)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
por: Heinemann, V, et al.
Publicado: (2013)

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2023)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Age-dependent expression of osteochondrosis-related genes in equine leukocytes
por: Mendoza, L., et al.
Publicado: (2015)

Phase II study of gemcitabine in patients with advanced pancreatic cancer.
por: Carmichael, J., et al.
Publicado: (1996)

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

A hemocyte gene expression signature correlated with predictive capacity of oysters to survive Vibrio infections
por: Rosa, Rafael Diego, et al.
Publicado: (2012)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
por: Schlick, Konstantin, et al.
Publicado: (2023)

Recurrent acute pancreatitis caused by combined gastric and pancreatic duplications: value of preoperative CT and MRCP and conservative surgery
por: Hérin, Edouard, et al.
Publicado: (2020)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
por: Blomstrand, Hakon, et al.
Publicado: (2020)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Recruitment of Glycosyl Hydrolase Proteins in a Cone Snail Venomous Arsenal: Further Insights into Biomolecular Features of Conus Venoms
por: Violette, Aude, et al.
Publicado: (2012)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy
por: Wang, Xiaoguang, et al.
Publicado: (2021)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Phase I trial of GBS‐01 for advanced pancreatic cancer refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2016)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q889bg7al1d7pu1qoentkujtt6